In a randomised, placebo-controlled trial including about 10 000 patients with type 2 diabetes and a mean HbA1c of 7.3% at enrolment, addition of dulaglutide to their usual hypoglycaemic therapy did not reduce all-cause or cardiovascular mortality after a follow-up of about 5 years. Acute pancreatitis, pancreatic cancer and thyroid cancer were more frequent in the dulaglutide group.
展开▼